Matches in SemOpenAlex for { <https://semopenalex.org/work/W3084496495> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W3084496495 endingPage "S7" @default.
- W3084496495 startingPage "S7" @default.
- W3084496495 abstract "Recent advancements in medical oncology have led to the development of multiple agents for the treatment of relapsed/refractory multiple myeloma (RRMM). These novel agents are generally given as combination therapies and have improved clinical outcomes such as progression-free survival (PFS). Given that patients are recommended for treatment till progression, this may lead to an increase in cost of treatment. The aim of this study was to compare drug treatment costs and drug cost per progression-free life year (PFLY) for the key regimens recommended for RRMM in Japan. List of regimens included in the analysis were based on RRMM treatment guidelines in Japan. These included doublet and triplet regimens containing the following agents: bortezomib (Bort), lenalidomide (Len), ixazomib (Ixa), panobinostat (Pano), carfilzomib (Carf), pomalidomide (Pom), elotuzumab (Elo), daratumumab (Dara), cyclophosphamide (Cyclo) and dexamethasone (Dex). Dosage, dosing schedule, duration of treatment (DOT) and PFS were obtained from published literature. Drug acquisition and administration costs were obtained from regional sources. Costs were cumulated over DOT to estimate per-patient total drug treatment cost which was then divided by PFS duration to estimate drug cost per PFLY for each regimen. The PFS varied from 4 months (PomDex) to 46 months (DaraLenDex). Total drug treatment cost for RRMM showed a wide variation. Drug costs were below ¥10M for BortDex, PomDex, BortCycloDex, and PanBortDex, between ¥10M-¥40M for CarfDex, LenDex, DaraBortDex, IxaLenDex, CarfLenDex and EloLenDex. DaraLenDex had the maximum treatment costs (>¥65M). Drug cost per PFLY ranged from ¥3M for BortCycloDex to ¥23M for EloLenDex. Cost of triplet regimens were generally higher than that for doublet regimens. Drug treatment cost in Japan varies significantly depending upon the regimen being prescribed to a patient with RRMM. Drug treatment cost per PFLY for newer regimens, that are mostly triplets, is substantially higher than doublet regimens." @default.
- W3084496495 created "2020-09-21" @default.
- W3084496495 creator A5010389020 @default.
- W3084496495 creator A5029735380 @default.
- W3084496495 creator A5066901675 @default.
- W3084496495 creator A5088960096 @default.
- W3084496495 date "2020-09-01" @default.
- W3084496495 modified "2023-09-30" @default.
- W3084496495 title "PCN16 Treatment Cost in Patients with Relapsed Refractory Multiple Myeloma in JAPAN" @default.
- W3084496495 doi "https://doi.org/10.1016/j.vhri.2020.07.066" @default.
- W3084496495 hasPublicationYear "2020" @default.
- W3084496495 type Work @default.
- W3084496495 sameAs 3084496495 @default.
- W3084496495 citedByCount "0" @default.
- W3084496495 crossrefType "journal-article" @default.
- W3084496495 hasAuthorship W3084496495A5010389020 @default.
- W3084496495 hasAuthorship W3084496495A5029735380 @default.
- W3084496495 hasAuthorship W3084496495A5066901675 @default.
- W3084496495 hasAuthorship W3084496495A5088960096 @default.
- W3084496495 hasBestOaLocation W30844964951 @default.
- W3084496495 hasConcept C126322002 @default.
- W3084496495 hasConcept C143998085 @default.
- W3084496495 hasConcept C2776063141 @default.
- W3084496495 hasConcept C2776364478 @default.
- W3084496495 hasConcept C2776694085 @default.
- W3084496495 hasConcept C2777478702 @default.
- W3084496495 hasConcept C2778524551 @default.
- W3084496495 hasConcept C2780108899 @default.
- W3084496495 hasConcept C2780739268 @default.
- W3084496495 hasConcept C2781098529 @default.
- W3084496495 hasConcept C2781119759 @default.
- W3084496495 hasConcept C2781413609 @default.
- W3084496495 hasConcept C71924100 @default.
- W3084496495 hasConceptScore W3084496495C126322002 @default.
- W3084496495 hasConceptScore W3084496495C143998085 @default.
- W3084496495 hasConceptScore W3084496495C2776063141 @default.
- W3084496495 hasConceptScore W3084496495C2776364478 @default.
- W3084496495 hasConceptScore W3084496495C2776694085 @default.
- W3084496495 hasConceptScore W3084496495C2777478702 @default.
- W3084496495 hasConceptScore W3084496495C2778524551 @default.
- W3084496495 hasConceptScore W3084496495C2780108899 @default.
- W3084496495 hasConceptScore W3084496495C2780739268 @default.
- W3084496495 hasConceptScore W3084496495C2781098529 @default.
- W3084496495 hasConceptScore W3084496495C2781119759 @default.
- W3084496495 hasConceptScore W3084496495C2781413609 @default.
- W3084496495 hasConceptScore W3084496495C71924100 @default.
- W3084496495 hasLocation W30844964951 @default.
- W3084496495 hasOpenAccess W3084496495 @default.
- W3084496495 hasPrimaryLocation W30844964951 @default.
- W3084496495 hasRelatedWork W2016202982 @default.
- W3084496495 hasRelatedWork W2478188943 @default.
- W3084496495 hasRelatedWork W2549893547 @default.
- W3084496495 hasRelatedWork W2615497162 @default.
- W3084496495 hasRelatedWork W2731606591 @default.
- W3084496495 hasRelatedWork W2920340622 @default.
- W3084496495 hasRelatedWork W2939294425 @default.
- W3084496495 hasRelatedWork W2981066129 @default.
- W3084496495 hasRelatedWork W2995945119 @default.
- W3084496495 hasRelatedWork W3114717300 @default.
- W3084496495 hasVolume "22" @default.
- W3084496495 isParatext "false" @default.
- W3084496495 isRetracted "false" @default.
- W3084496495 magId "3084496495" @default.
- W3084496495 workType "article" @default.